GlassScriptPhysician profile
Christopher P Roth
NPI 1679890974
$2,426.25
in general payments reported to CMS, 2019-2025
20 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $117 · 2021: $284 · 2022: $511 · 2023: $234 · 2024: $386 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $451.82 | 2019-2024 | |
| Pfizer INC. | $306.61 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $252.43 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $228.07 | 2019-2021 | |
| Amgen INC. | $166.39 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $154.00 | 2019-2025 | Watchman Access System, General - Structural Heart, Resonate El Icd Vr |
| Edwards Lifesciences Corporation | $153.85 | 2025 | Pascal |
| Siemens Medical Solutions USA, INC. | $102.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $102.35 | 2019-2024 | Wainua |
| Regeneron Healthcare Solutions, INC. | $95.40 | 2019-2023 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.17 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $70.42 | 2023-2025 | Verquvo, Winrevair |
| Sanofi-Aventis U.S. LLC | $62.66 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.35 | 2022-2024 | Lifevest |
| Scpharmaceuticals INC. | $36.74 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $24.75 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.52 | 2022 | |
| Abbott Laboratories | $21.14 | 2023 | Mitraclip |
| Otsuka America Pharmaceutical, INC. | $20.76 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.05 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.